25th November 2024 by Dr Louise Hudman
This is a new guideline from NICE published in Jul 2024.
It advises that CYP2C19 genotype testing can be carried out on certain people to see if they will respond to clopidogrel.
People who have just had an ischaemic stroke or TIA. It is anticipated that at first this technology won’t be available for many people, so it will be targeted at those most likely to benefit.
Vibegron in overactive bladder syndrome (Nice, 2024)
Like Mirabegron, Vibegron is also a beta-3 adrenergic receptor agonist.
Last chance to sign up for free GP physical activity webinar
GP speaker Dr Varun Anand will present ‘Physical activity for long-term conditions’ for NASGP’s last webinar of 2024.
Genetic testing for clopidogrel response (Nice 2024)
It advises that CYP2C19 genotype testing can be carried out on certain people to see if they will respond to clopidogrel.
"I am a newly qualified sessional GP. I am thankful to you and your team for the splendid work you do for all of us. LocumDeck is the only platform that allows GPs to be in control and I am glad I have been a member of NASGP since my trainee days."
Dr Karthik Krishna, GP